Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1065890 versus placebo in adults with tardive dyskinesia
2025-524104-30-00Phase 2Authorised
- Sponsor
- Neurocrine Biosciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in tardive dyskinesia (TD) comparing NBI-1065890 with Placebo (2 arms). Primary endpoint: Change from baseline in AIMS Dyskinesia Total Score at Week 8. Planned start Sep 2026; status: authorised.
02
Drugs
NBI-1065890
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on 2025-524104-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524104-30-00.